1-(4-methyl-1H-pyrrol-2-yl)ethanone | 40611-72-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(4-methyl-1H-pyrrol-2-yl)ethanone
• CAS: 40611-72-1
• 化学式: C₇H₉NO
• 分子量: 123.15
• InChiKey: FTZSIAYCTJFZPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  32.9
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS
  申请人：TACHDJIAN Catherine

  公开号：US20130295261A1

  公开（公告）日：2013-11-07

  The present invention provides isosorbide derivatives having the formula shown below and certain subgenera or species thereof, as flavor or taste modifiers, particularly, savory (“umami”) taste modifiers, savory flavoring agents and savory flavor enhancers in foods, beverages, and other comestible compositions,

  本发明提供以下式子及其特定亚属或种类的异山梨酯衍生物，作为味道或口感调节剂，特别是让食品、饮料和其他食品组合物具有鲜美（鲜味）口感的调节剂、风味剂和风味增强剂。
• AMIDES AS PIM INHIBITORS
  申请人：AMGEN INC.

  公开号：US20150329538A1

  公开（公告）日：2015-11-19

  The invention relates to amide-containing compounds of formula (1), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

  本发明涉及公式（1）的含酰胺化合物及其盐。在某些实施例中，本发明涉及Pim-1和/或Pim-2和/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，本发明涉及包含所述化合物的药物组合物，以及它们在预防和治疗与Pim激酶相关的疾病和病症，尤其是癌症方面的用途。
• PROCESS FOR THE PREPARATION OF N,N-DICYCLOPROPYL-4-(1,5-DIMETHYL-1H-PYRAZOL-3-YLAMINO)-6-ETHYL-1-METHYL-1,6-DIHYDROIMIDAZO[4,5-d]PYRROLO[2,3-b]PYRIDINE-7-CARBOXAMIDE
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160229854A1

  公开（公告）日：2016-08-11

  The invention relates to an improved process for synthesizing N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide of the formula: (I) Compound (I) is currently in clinical trials for the treatment of myeloproliferative disorders, such as polycythaemia vera, thrombocythaemia and primary myelofibrosis.
• COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
  申请人：NOVARTIS AG

  公开号：US20170333437A1

  公开（公告）日：2017-11-23

  The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.
• US8420145B2
  申请人：——

  公开号：US8420145B2

  公开（公告）日：2013-04-16